March, 2025
March 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
31  
Patrick Hwu: AntiPD1 in combination with antilag3 and ctla4 in head and neck cancers
Mar 17, 2025, 13:32

Patrick Hwu: AntiPD1 in combination with antilag3 and ctla4 in head and neck cancers

Patrick HwuPresident and CEO of Moffitt Cancer Center, shared an article by Housaiyin Li, et al. on LinkedIn:

“Increasing evidence suggests giving immunotherapy before surgery (neoadjuvant) is better than after surgery (adjuvant).

In a recent report investigators compared neoadjuvant single agent anti-PD1 to combinations with anti-PD1 and either anti-LAG3 or anti-CTLA4 antibodies in patients with head and neck cancers.

Both combinations were more effective than single agent but the combination with anti-CTLA4 had more toxicity. In addition the combinations activated different T cell populations. The combination with anti-CTLA4 activated effector CD8 T cells in the tumor whereby the combination with anti-LAG3 was capable of reprogramming some exhausted CD8 T cell populations.

Understanding the mechanisms of these immunotherapy combinations will enhance our ability to personalize and optimize immunotherapy to improve outcomes.

Here’s a link to the full article.”

Patrick Hwu: AntiPD1 in combination with antilag3 and ctla4 in head and neck cancers

Distinct CD8+ T cell dynamics associate with response to neoadjuvant cancer immunotherapies.

Authors: Housaiyin Li, et al.

Patrick Hwu: AntiPD1 in combination with antilag3 and ctla4 in head and neck cancers